Duvelisib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Duvelisib
Accession Number
DB11952
Type
Small Molecule
Groups
Investigational
Description

Duvelisib has been used in trials studying the treatment and basic science of Lymphoma, Leukemia, T-cell Lymphoma, Hepatic Impairment, and Follicular Lymphoma, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
INK-1197 / IPI-145
Categories
UNII
610V23S0JI
CAS number
1201438-56-3
Weight
Average: 416.87
Monoisotopic: 416.1152369
Chemical Formula
C22H17ClN6O
InChI Key
SJVQHLPISAIATJ-ZDUSSCGKSA-N
InChI
InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1
IUPAC Name
8-chloro-2-phenyl-3-[(1S)-1-[(9H-purin-6-yl)amino]ethyl]-1,2-dihydroisoquinolin-1-one
SMILES
C[C@H](NC1=C2N=CNC2=NC=N1)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Duvelisib.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Duvelisib is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Duvelisib is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Duvelisib is combined with 5-androstenedione.Experimental, Illicit
AbciximabDuvelisib may increase the anticoagulant activities of Abciximab.Approved
AcebutololDuvelisib may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Duvelisib is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Duvelisib is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolDuvelisib may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Duvelisib is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Duvelisib.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Duvelisib is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Duvelisib is combined with Alendronic acid.Approved
AliskirenDuvelisib may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Duvelisib is combined with Alminoprofen.Experimental
AlprenololDuvelisib may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Duvelisib.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Amcinonide.Approved
AmilorideDuvelisib may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Duvelisib is combined with Aminosalicylic Acid.Approved
AncrodDuvelisib may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Duvelisib.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Duvelisib is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Duvelisib is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Duvelisib.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Duvelisib is combined with Antipyrine.Approved, Investigational
Antithrombin III humanDuvelisib may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Duvelisib is combined with Antrafenine.Approved
ApixabanDuvelisib may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Duvelisib is combined with Apocynin.Investigational
ApramycinDuvelisib may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Duvelisib.Approved, Investigational
ArbekacinDuvelisib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinDuvelisib may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanDuvelisib may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololDuvelisib may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineDuvelisib may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Atamestane.Investigational
AtenololDuvelisib may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Duvelisib.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Duvelisib.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Duvelisib is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Duvelisib.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Duvelisib.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Balsalazide.Approved, Investigational
BecaplerminDuvelisib may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BefunololDuvelisib may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinDuvelisib may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Duvelisib is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Duvelisib.Approved
BenorilateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Duvelisib.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Duvelisib.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Duvelisib is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Duvelisib.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Betamethasone.Approved, Vet Approved
BetaxololDuvelisib may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Duvelisib.Approved, Investigational
BevantololDuvelisib may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Duvelisib is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Duvelisib.Approved, Investigational
BisoprololDuvelisib may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinDuvelisib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololDuvelisib may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Duvelisib is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Duvelisib is combined with Bucillamine.Investigational
BucindololDuvelisib may decrease the antihypertensive activities of Bucindolol.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Duvelisib is combined with Bufexamac.Approved, Experimental
BufuralolDuvelisib may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Duvelisib.Approved
BupranololDuvelisib may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Duvelisib.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Duvelisib.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Duvelisib is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Duvelisib is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Duvelisib.Approved
CarprofenThe risk or severity of adverse effects can be increased when Duvelisib is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololDuvelisib may decrease the antihypertensive activities of Carteolol.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Duvelisib.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Celecoxib.Approved, Investigational
CeliprololDuvelisib may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinDuvelisib may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Duvelisib.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Duvelisib.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Duvelisib is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Duvelisib.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Duvelisib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Cimicoxib.Investigational
CinoxacinDuvelisib may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CisplatinThe risk or severity of adverse effects can be increased when Duvelisib is combined with Cisplatin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Duvelisib is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Duvelisib is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Duvelisib.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Duvelisib.Vet Approved
CloranololDuvelisib may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Duvelisib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Duvelisib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Duvelisib.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Duvelisib.Experimental
Dabigatran etexilateDuvelisib may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinDuvelisib may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidDuvelisib may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanDuvelisib may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Duvelisib is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Duvelisib is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Delapril.Investigational
DesipramineDuvelisib may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinDuvelisib may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Duvelisib is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Duvelisib is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Duvelisib.Approved, Investigational
DextranDuvelisib may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinDuvelisib may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Duvelisib is combined with Dibotermin alfa.Approved, Investigational
DicoumarolDuvelisib may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Duvelisib is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Duvelisib.Approved
DihydrostreptomycinDuvelisib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Duvelisib.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Duvelisib.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Duvelisib.Approved
DrospirenoneDuvelisib may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Duvelisib is combined with Droxicam.Withdrawn
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Duvelisib.Investigational
Edetic AcidDuvelisib may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanDuvelisib may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Duvelisib is combined with Enalaprilat.Approved
EnoxacinDuvelisib may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinDuvelisib may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Duvelisib.Experimental
EpanololDuvelisib may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Duvelisib.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Duvelisib.Experimental
EplerenoneDuvelisib may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Duvelisib.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Duvelisib.Approved
EquileninThe risk or severity of adverse effects can be increased when Duvelisib is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Duvelisib is combined with Equilin.Approved
EsatenololDuvelisib may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololDuvelisib may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Duvelisib.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Duvelisib is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Ethenzamide.Experimental
Ethyl biscoumacetateDuvelisib may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Duvelisib is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Duvelisib is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Duvelisib.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Duvelisib.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Duvelisib.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Duvelisib.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Duvelisib.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Duvelisib.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Feprazone.Experimental
Ferulic acidDuvelisib may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Duvelisib.Approved, Investigational
FleroxacinDuvelisib may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Duvelisib.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fludrocortisone.Approved, Investigational
FluindioneDuvelisib may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineDuvelisib may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Duvelisib.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Duvelisib is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Duvelisib.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Duvelisib is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluticasone furoate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Duvelisib.Approved, Nutraceutical, Vet Approved
FondaparinuxDuvelisib may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Duvelisib.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Formestane.Approved, Investigational, Withdrawn
FramycetinDuvelisib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
GabexateDuvelisib may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinDuvelisib may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinDuvelisib may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Duvelisib.Approved, Withdrawn
GemifloxacinDuvelisib may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinDuvelisib may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinDuvelisib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ADuvelisib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Duvelisib is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinDuvelisib may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Duvelisib is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Duvelisib is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Duvelisib is combined with HE3286.Investigational
HeparinDuvelisib may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Duvelisib is combined with Higenamine.Investigational
HydralazineDuvelisib may decrease the antihypertensive activities of Hydralazine.Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Duvelisib.Approved, Investigational
Hygromycin BDuvelisib may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Duvelisib.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Duvelisib.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Duvelisib is combined with Icosapent.Approved, Nutraceutical
IdraparinuxDuvelisib may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Duvelisib.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Duvelisib.Approved
IndenololDuvelisib may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Duvelisib is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Duvelisib is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Duvelisib.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Duvelisib.Approved, Investigational
IsepamicinDuvelisib may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Duvelisib.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Duvelisib is combined with Istaroxime.Investigational
KanamycinDuvelisib may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Duvelisib.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Duvelisib is combined with Ketoprofen.Approved, Vet Approved
LandiololDuvelisib may decrease the antihypertensive activities of Landiolol.Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Duvelisib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Duvelisib.Approved, Investigational
LepirudinDuvelisib may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanDuvelisib may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololDuvelisib may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololDuvelisib may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinDuvelisib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Duvelisib.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Duvelisib is combined with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Duvelisib.Experimental
LomefloxacinDuvelisib may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Duvelisib is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Duvelisib is combined with Lornoxicam.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Duvelisib is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Duvelisib.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Duvelisib.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Duvelisib.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Duvelisib.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Duvelisib is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Duvelisib is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Duvelisib is combined with Mefenamic acid.Approved
MelagatranDuvelisib may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Duvelisib is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Duvelisib is combined with Meloxicam.Approved, Vet Approved
MepindololDuvelisib may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Duvelisib is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Duvelisib.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Duvelisib.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Duvelisib.Approved
MetipranololDuvelisib may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Duvelisib.Approved
MicronomicinDuvelisib may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Duvelisib.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Duvelisib.Approved
MizoribineThe risk or severity of adverse effects can be increased when Duvelisib is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Duvelisib.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Duvelisib.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Duvelisib.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Nabumetone.Approved
NadololDuvelisib may decrease the antihypertensive activities of Nadolol.Approved
NadroparinDuvelisib may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatDuvelisib may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Duvelisib.Approved
Nalidixic AcidDuvelisib may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Duvelisib is combined with NCX 1022.Investigational
NeamineDuvelisib may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololDuvelisib may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinDuvelisib may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Duvelisib is combined with Nepafenac.Approved, Investigational
NetilmicinDuvelisib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Duvelisib is combined with Niflumic Acid.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Duvelisib is combined with Nitroaspirin.Investigational
NorfloxacinDuvelisib may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinDuvelisib may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Duvelisib.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Duvelisib.Approved
OlsalazineDuvelisib may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Duvelisib is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Duvelisib is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Duvelisib.Vet Approved
OtamixabanDuvelisib may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Duvelisib is combined with Oxaprozin.Approved
Oxolinic acidDuvelisib may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololDuvelisib may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Duvelisib.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Duvelisib is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Parecoxib.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Parthenolide.Approved, Investigational
PazufloxacinDuvelisib may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinDuvelisib may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololDuvelisib may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateDuvelisib may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateDuvelisib may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Perindopril.Approved
PhenindioneDuvelisib may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonDuvelisib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Duvelisib.Approved, Investigational
PindololDuvelisib may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidDuvelisib may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Duvelisib.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Duvelisib.Approved, Investigational
Piromidic acidDuvelisib may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Duvelisib is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Duvelisib is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Duvelisib is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorDuvelisib may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinDuvelisib may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Duvelisib.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Pomalidomide.Approved
Potassium CitrateDuvelisib may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololDuvelisib may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Duvelisib.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Duvelisib is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Prednicarbate.Approved, Investigational
PrednisoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Duvelisib can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Duvelisib is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Duvelisib.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Duvelisib.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Duvelisib.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Duvelisib.Vet Approved
Protein CDuvelisib may increase the anticoagulant activities of Protein C.Approved
Protein S humanDuvelisib may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDuvelisib may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinDuvelisib may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Duvelisib.Investigational
PuromycinDuvelisib may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Duvelisib.Approved
RamiprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Duvelisib is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Duvelisib is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinDuvelisib may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinDuvelisib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Risedronate.Approved, Investigational
RivaroxabanDuvelisib may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinDuvelisib may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinDuvelisib may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Duvelisib.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Duvelisib.Approved
SalsalateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Duvelisib.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Duvelisib.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Duvelisib is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Duvelisib.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Duvelisib is combined with Serrapeptase.Investigational
SisomicinDuvelisib may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinDuvelisib may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SotalolDuvelisib may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinDuvelisib may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Duvelisib.Investigational
StreptomycinDuvelisib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulodexideDuvelisib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Duvelisib.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Duvelisib is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Suxibuzone.Experimental
TacrolimusDuvelisib may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Duvelisib.Approved
TalinololDuvelisib may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Duvelisib.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Duvelisib.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Duvelisib.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Duvelisib is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Duvelisib.Approved, Investigational
TemafloxacinDuvelisib may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Duvelisib is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Duvelisib is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Duvelisib.Vet Approved
TerbutalineDuvelisib may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Duvelisib.Approved
TertatololDuvelisib may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Duvelisib is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Duvelisib is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololDuvelisib may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Duvelisib is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Duvelisib is combined with Tixocortol.Approved, Withdrawn
TobramycinDuvelisib may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Duvelisib is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Duvelisib.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Duvelisib.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Duvelisib.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Duvelisib is combined with Triamcinolone.Approved, Vet Approved
TriamtereneDuvelisib may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Duvelisib.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Duvelisib is combined with Triptolide.Investigational
TrovafloxacinDuvelisib may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinDuvelisib may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Duvelisib is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Duvelisib.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Duvelisib.Approved, Investigational
WarfarinDuvelisib may increase the anticoagulant activities of Warfarin.Approved
XimelagatranDuvelisib may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Duvelisib.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Duvelisib.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Duvelisib is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Duvelisib.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D10555
PubChem Compound
50905713
PubChem Substance
347828278
ChemSpider
28637766
ChEBI
131169
ChEMBL
CHEMBL3039502
Wikipedia
Duvelisib

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers5
1CompletedBasic ScienceHepatic Impairment1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL) / T-Cell Lymphomas1
1CompletedTreatmentMalignant Lymphomas1
1RecruitingTreatmentMalignant Lymphomas / Relapsed/Refractory T-cell Lymphomas1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
1TerminatedTreatmentMalignancies, Hematologic1
1WithdrawnTreatmentChronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL)1
1, 2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2CompletedTreatmentCD20+ Follicular Lymphoma1
1, 2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2Active Not RecruitingTreatmentIndolent Non-Hodgkin's Lymphomas1
2Active Not RecruitingTreatmentMalignancies, Hematologic1
2CompletedTreatmentRheumatoid Arthritis1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
2WithdrawnTreatmentLeukemias1
2WithdrawnTreatmentMalignant Lymphomas1
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
3Enrolling by InvitationTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
3TerminatedTreatmentFollicular Lymphoma (FL)1
3WithdrawnTreatmentFollicular Lymphoma (FL) / Indolent Non-Hodgkin's Lymphomas / Marginal Zone Lymphoma / Small Lymphocytic Lymphoma (SLL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0195 mg/mLALOGPS
logP3.91ALOGPS
logP3.67ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)9.86ChemAxon
pKa (Strongest Basic)3.99ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area86.8 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity118.53 m3·mol-1ChemAxon
Polarizability42.2 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as isoquinolones and derivatives. These are aromatic polycyclic compounds containing a ketone bearing isoquinoline moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoquinolines and derivatives
Sub Class
Isoquinolones and derivatives
Direct Parent
Isoquinolones and derivatives
Alternative Parents
6-alkylaminopurines / Secondary alkylarylamines / Pyridinones / Aminopyrimidines and derivatives / Aryl chlorides / Benzene and substituted derivatives / Imidolactams / Vinylogous halides / Imidazoles / Heteroaromatic compounds
show 7 more
Substituents
Isoquinolone / 6-alkylaminopurine / 6-aminopurine / Imidazopyrimidine / Purine / Aminopyrimidine / Pyridinone / Secondary aliphatic/aromatic amine / Aryl chloride / Aryl halide
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:04 / Updated on August 02, 2018 06:31